TY  - GEN
AU  - Pérez-Belmonte, Luis M
AU  - Sanz-Cánovas, Jaime
AU  - García de Lucas, María D
AU  - Ricci, Michele
AU  - Avilés-Bueno, Beatriz
AU  - Cobos-Palacios, Lidia
AU  - Pérez-Velasco, Miguel A
AU  - López-Sampalo, Almudena
AU  - Bernal-López, M Rosa
AU  - Jansen-Chaparro, Sergio
AU  - Miramontes-González, José P
AU  - Gómez-Huelgas, Ricardo
PY  - 2022
DO  - 10.3389/fendo.2022.851035
SN  - 1664-2392
UR  - http://hdl.handle.net/20.500.12105/18686
AB  - The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with...
LA  - eng
KW  - health status
KW  - heart failure
KW  - obesity
KW  - semaglutide
KW  - type 2 diabetes
KW  - Diabetes Mellitus, Type 2
KW  - Glucagon-Like Peptide-1 Receptor
KW  - Glucagon-Like Peptides
KW  - Heart Failure
KW  - Humans
KW  - Obesity
KW  - Retrospective Studies
TI  - Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
TY  - research article
ER  -